title: ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?
authors.forename: Laura
authors.initials: L
authors.lastname: Milazzo
authors.forename: Dario
authors.initials: D
authors.lastname: Cattaneo
authors.forename: Stefania
authors.initials: S
authors.lastname: Cheli
authors.forename: Laurenzia
authors.initials: L
authors.lastname: Ferraris
authors.forename: Elisa
authors.initials: E
authors.lastname: Colella
authors.forename: Emilio
authors.initials: E
authors.lastname: Clementi
authors.forename: Cristina
authors.initials: C
authors.lastname: Gervasoni
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003371:Cough / Q000139:chemically induced* / Q000235:genetics / Q000503:physiopathology; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a